-
Stoic Verstappen looking beyond 'painful' Monza weekend
-
Senegal has an IMF loan, now what?
-
OpenAI begins rollout of new powerful AI model GPT-6 Astra
-
Auger-Aliassime upset by Khachanov at US Open
-
FIFA blasts UEFA 'smear campaign,' fights World Cup plan disclosures
-
Hugging Face, the French start-up that became AI's warehouse
-
Zelensky hopes to host US envoys in Kyiv in 'coming days'
-
World Cup winner Llorente retires from Spain team at 31
-
Martinelli joins Al-Hilal from Arsenal for reported £60 million
-
Osaka squeezes into US Open third round
-
Tesla's semi-autonomous driving could be adapted to EU norms: France
-
Apple faces £2 bn lawsuit in UK over app privacy feature
-
37 people die from fumes during oil pipeline theft in Nigeria: NGO
-
Former champ Swiatek eases into US Open third round
-
Ahead of elections, Israel tests West's patience on West Bank violence
-
DR Congo latest to promise moving Israel embassy to Jerusalem
-
Antonelli will obey Mercedes orders to help 'tow' teammate Russell
-
War criminal Mladic's body returns to Serbia with military honours
-
UK fintech Revolut gains conditional US banking licence
-
Pierre Cardin museum brings designer's futurist style to Venice
-
Mara sisters channel childhood energy for twins performance at Venice
-
Slovenian rookie Omrzel triumphs as Mas extends Vuelta lead
-
UN's Sudan probe says foreign fighters fuelling conflict
-
British, French leaders talk migrants, EU relations
-
Violence erupts at S.Africa anti-migrant protest
-
Heading for Ferrari's home race, Leclerc still dreams of world title
-
Nothing left: Nepal flood survivors face loss and uncertainty
-
Cafe at centre of Israel culture clash agrees to shut on Sabbath
-
Tesla to launch self-driving 'Cybercab' in Texas
-
Spacecraft bound for Mercury begins 'tricky' arrival
-
Europe struggles to respond as Russia escalates shadow warfare
-
Initial expert report blames tanker for collision off Istanbul
-
Malta PM urges 'caution' after acquittal in journalist's murder
-
'Everyone a winner' with Barcola transfer, says PSG coach Luis Enrique
-
Spanish PM says no 'solid proof' Morocco planned Ceuta migrant rush
-
Ukraine, India discuss Black Sea, food security on FM's 'historic' Kyiv visit
-
Venezuela's Maduro seek immunity from US drug charges
-
Europe bids to be robot superpower like US, China
-
Tazapay Now Live on the Borderless.xyz Network For Seamless Money Movement to Asia Pacific and Latin America
-
US Fed official joins growing group open to rate hike if inflation rises
-
DWF Labs Expands Global Regulatory Footprint with BVI Virtual Asset Service Provider Approval
-
Hugh Jackman in talks to buy stake in Norwich football club
-
Just the beginning of the journey, Broeders-Bol says of 800m adventure
-
Yen surges on new intervention talk, oil prices climb
-
US trade gap in July hits biggest in over a year on AI buildout
-
US feminist icon Gloria Steinem dies aged 92
-
Study shows plug-in hybrids polluting far more than expected
-
France recorded 'hottest summer ever': environment minister
-
Lost tool disrupted Airbus jet deliveries for months
-
'No plans to retire', says 'acting god' Malkovich
Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 11, 2025
HACKENSACK, NJ / ACCESS Newswire / March 6, 2025 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the third quarter ended January 31, 2025, on Tuesday, March 11, 2025, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 403045. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode:52158, or by accessing the investors section of the company's website within 72 hours.
About Champions Oncology, Inc.
Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.
Media Inquiries:
Rachel Bunting, MS, MBA
VP, Global Marketing
[email protected]
Website: https://www.championsoncology.com/
Facebook: https://www.facebook.com/championsoncology/
LinkedIn: https://www.linkedin.com/company/champions-oncology-inc-/
Twitter: @ChampionsOncol1
Instagram: https://www.instagram.com/championsoncology/
SOURCE: Champions Oncology, Inc.
View the original press release on ACCESS Newswire
T.Wright--AT